Dawson James analyst Jason Kolbert maintained a Buy rating on Pluristem (PSTI – Research Report) on May 10 and set a price target of $9.00. The company's shares closed last Friday at $1.46, close to its 52-week low of $1.35. According to TipRanks.com, Kolbert 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -3.6% and a 33.9% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Lineage Cell Therapeutics, Citius Pharmaceuticals, and Sorrento Therapeutics. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Pluristem with a $9.00 average price target.
https://www.tipranks.com/news/blurbs/dawson-james-thinks-pluristems-stock-is-going-to-recover?utm_source=advfn.com&utm_medium=referral
Pluristem Therapeutics (NASDAQ:PSTI)
Historical Stock Chart
From Nov 2022 to Dec 2022 Click Here for more Pluristem Therapeutics Charts.
Pluristem Therapeutics (NASDAQ:PSTI)
Historical Stock Chart
From Dec 2021 to Dec 2022 Click Here for more Pluristem Therapeutics Charts.